Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.

NCT03339661 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplant Infection

Interventions

DRUG: Group 1_No proph treatment
DRUG: Group 2A_Proph treatment and γδ T cell expansion
DRUG: Group 2B_Proph treatment and no γδ T cell expansion

Sponsor

University Hospital, Bordeaux